Drug and Health Product Submissions Under Review (SUR): New drug submissions under review

Submissions currently under review: New drug submissions
Medicinal Ingredient(s) Therapeutic Area Year, Month Submission was Accepted into Review Company Name (available for submissions accepted into review on or after October 1, 2018) Submission 'Class' (if applicable) (available for submissions accepted into review on or after October 1, 2018)
Abrocitinib Other dermatological preparations 2020-12 Pfizer Canada ULC New active substance

Part of 'aligned review' with a health technology assessment organization

Acetaminophen Analgesics 2021-04 B. Braun Melsungen AG Being reviewed under the Submissions Relying on Third-Party Data Guidance
Ad26.COV2.S (recombinant)** Vaccines 2021-06* Janssen Inc For use in relation to COVID-19

New active substance

Adalimumab Immunosuppressants 2021-02 Jamp Pharma Corporation Biosimilar
Adalimumab Immunosuppressants 2021-03 Celltrion Healthcare Co Ltd Biosimilar
Aducanumab Other nervous system drugs 2021-06 Biogen Canada Inc New active substance
Alfa 1-proteinase inhibitor (human) Antihemorrhagics 2021-01 Takeda Canada Inc Not applicable
Anifrolumab Immunosuppressants 2020-12 AstraZeneca Canada Inc New active substance
Aprotinin Antihemorrhagics 2021-02 Nordic Group B.V. Not applicable
Avacopan Immunosuppressants 2021-05 Vifor Fresenius Medical Care Renal Pharma Ltd New active substanced
Avalglucosidase alfa Other alimentary tract and metabolism 2020-11 Sanofi-Aventis Canada Inc New active substance
Avanafil Urologicals 2019-06 Acerus Pharmaceuticals Corporation New active substance
Avatrombopag maleate Antihemorrhagics 2021-06 Swedish Orphan Biovitrum AB (publ) New active substance
Bamlanivimab** Immune sera and immunoglobulins 2021-06* Eli Lilly Canada Inc For use in relation to COVID-19

New active substance

Belumosudil mesylate Immunosuppressants 2021-01 Kadmon Pharmaceuticals LLC New active substance

Being reviewed under the Priority Review Policy

Bendamustine hydrochloride Antineoplastic agents 2021-03 Pfizer Canada ULC Not applicable
Bevacizumab Antineoplastic agents 2020-07 BGP Pharma ULC Biosimilar
Bevacizumab Antineoplastic agents 2020-10 Centus Biotherapeutics Limited Biosimilar
Bevacizumab
(2 submissions under review)
Antineoplastic agents 2021-02 Samsung Bioepis Co., Ltd Biosimilar
Bimekizumab Immunosuppressants 2021-04 UCB Canada Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Budesonide, formoterol fumarate dihydrate, glycopyrronium bromide Drugs for obstructive airway diseases 2020-09 AstraZeneca Canada Inc Part of 'aligned review' with a health technology assessment organization
Bupivacaine Anesthetics 2019-12 Pacira Limited Not applicable
Bupivacaine, meloxicam Antiinflammatory and antirheumatic products 2020-01 Heron Therapeutics, Inc. Not applicable
Captopril Agents acting on the renin-angiotensin system 2021-04 Ethypharm Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance
Cariprazine hydrochloride Psycholeptics 2021-06 Allergan Inc New active substance
Cevimeline hydrochloride Other nervous system drugs 2020-09 KYE Pharmaceuticals Inc New active substance
ChAdOx1-S (recombinant)** Vaccines 2021-06* AstraZeneca Canada Inc For use in relation to COVID-19

New active substance

Cilostazol Antithrombotic agents 2021-02 KYE Pharmaceuticals Inc New active substance

Being reviewed under the Submissions Relying on Third-Party Data Guidance
Colchicine Antigout preparations 2021-02 Pendopharm Division of Pharmascience Inc Being reviewed under the Priority Review Policy

Part of 'aligned review' with a health technology assessment organization
Copper, manganese sulfate, selenious acid, sodium iodide, zinc sulfate Blood substitutes and perfusion solutions 2021-03 Sandoz Canada Incorporated Being reviewed under the Submissions Relying on Third-Party Data Guidance
Corynebacterium diphtheria CRM-197 protein, pneumococcal polysaccharide serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F, and 33F Vaccines 2021-01 Merck Canada Inc New active substance
Dequalinium chloride Gynecological antiinfectives and antiseptics 2019-07 Duchesnay Inc Not applicable
Diroximel fumarate Immunosuppressants 2020-07 Biogen Canada Inc New active substance
Dostarlimab Antineoplastic agents 2021-04 GlaxoSmithKline Inc New active substance

Being reviewed under the Notice of Compliance with Conditions Guidance

Dronabinol Antiemetics and antinauseants 2021-05 Tetra Bio-Pharma Inc. Being reviewed under the Submissions Relying on Third-Party Data Guidance
Drospirenone Sex hormones and modulators of the genital system 2021-02 Duchesnay Inc Not applicable
Enfortumab vedotin Antineoplastic agents 2021-05 Seagen Inc. New active substance

Being reviewed under the Priority Review Policy

Part of 'aligned review' with a health technology assessment organization
Etanercept Immunosuppressants 2020-02 Lupin Pharma Canada Limited Biosimilar
Filgrastim (r-metHuG-CSF) Immunostimulants 2019-03 Tanvex Biopharm USA, Inc Biosimilar
Finerenone Diuretics 2021-04 Bayer Inc New active substance
Fostemsavir tromethamine Antivirals for systemic use 2021-04 Viiv Healthcare ULC New active substance

Being reviewed under the Priority Review Policy
Gallium Ga 68-PSMA-11 Diagnostic radiopharmaceuticals 2021-02 Telix Pharmaceuticals (US) Inc New active substance

Being reviewed under the Submissions Relying on Third-Party Data Guidance
Gallium oxodotreotide Diagnostic radiopharmaceuticals 2021-05 Canadian Molecular Imaging Probe Consortium (CanProbe) New active substance
Ganciclovir Ophthalmologicals 2019-02 Laboratoires Thea Not applicable
Goserelin acetate Endocrine therapy 2020-07 JAMP Pharma Corporation Not applicable
Human insulin (recombinant) Drugs used in diabetes 2021-05 Baxter Corporation Biosimilar
Hyaluronidase (human recombinant), immunoglobulin (human), Immune sera and immunoglobulins 2021-02 Takeda Canada Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Inclisiran sodium Lipid modifying agents 2020-09 Novartis Pharmaceuticals Canada Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Infigratinib phosphate Antineoplastic agents 2021-01 QED Therapeutics, Inc. New active substance

Being reviewed under the Notice of Compliance with Conditions Guidance

Infliximab Immunosuppressants 2021-02 Pfizer Canada ULC Biosimilar
Insulin aspart Drugs used in diabetes 2020-12 BGP Pharma ULC Biosimilar
Insulin glargine Drugs used in diabetes 2021-06 BGP Pharma ULC Biosimilar
Insulin lispro Drugs used in diabetes 2020-11 Eli Lilly Canada Inc Not applicable
Leuprolide mesylate Endocrine therapy 2021-01 Accord Healthcare Inc Not applicable
Lisocabtagene maraleucel Antineoplastic agents 2021-02 Celgene Inc New active substance
Lurbinectedin Antineoplastic agents 2021-01 Jazz Pharmaceuticals Ireland Limited New active substance

Being reviewed under the Notice of Compliance with Conditions Guidance
Macitentan, tadalafil Antihypertensives 2020-12 Janssen Inc Not applicable
Mesalazine Antidiarrheals, intestinal anti-inflammatory/anti-infective agents 2021-03 Avir Pharma Inc Not applicable
Methylphenidate hydrochloride Psychoanaleptics 2021-01 KYE Pharmaceuticals Inc Not applicable
Mogamulizumab Antineoplastic agents 2021-05 Kyowa Kirin, Inc. New active substance
Mometasone furoate monohydrate, olopatadine hydrochloride Nasal preparations 2020-07 Glenmark Specialty SA Not applicable
mRNA-1273 SARS-CoV-2** Vaccines 2021-06* ModernaTX, Inc For use in relation to COVID-19

New active substance

Ospemifene Sex hormones and modulators of the genital system 2019-03 Duchesnay Inc New active substance
Pegfilgrastim Immunostimulants 2019-11 Purdue Pharma Biosimilar
Pegvaliase Other alimentary tract and metabolism products 2021-06 BioMarin International Limited New active substance
Pemigatinib Antineoplastic agents 2020-10 Incyte Corporation New active substance

Part of 'aligned review' with a health technology assessment organization
Pralsetinib Antineoplastic agents 2021-06 Hoffmann La Roche Limited Being reviewed under the Notice of Compliance with Conditions Guidance
Ranibizumab Ophthalmologicals 2021-05 Samsung Bioepis Co., Ltd Biosimilar
Recombinant haemagglutinin-strain A (H1N1) virus-like particles, Recombinant haemagglutinin-strain A (H3N2) virus-like particles, Recombinant haemagglutinin-strain B (Victoria lineage) virus-like particles, Recombinant haemagglutinin-strain B (Yamagata lineage) virus-like particles Vaccines 2019-09 Medicago Inc New active substance
Regdanvimab Immune sera and immunoglobulins 2021-05* Celltrion HealthCare Co Ltd For use in relation to COVID-19

New active substance

Roxadustat Antianemic preparations 2020-03 AstraZeneca Canada Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Sacituzumab govitecan Antineoplastic agents 2021-03 Gilead Sciences Canada Inc New active substance

Being reviewed under the Priority Review Policy
Selumetinib Antineoplastic agents 2020-11 AstraZeneca Canada Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Semaglutide Drugs used in diabetes 2021-01 Novo Nordisk Canada Inc Not applicable
Somatrogon Pituitary, hypothalamic hormones and analogues 2020-12 Pfizer Canada ULC New active substance
Sotorasib Antineoplastic agents 2021-02 Amgen Canada Inc New active substance

Being reviewed under the Notice of Compliance with Conditions Guidance
Tafamidis Other nervous system drugs 2020-09 Pfizer Canada ULC Not applicable
Tafasitamab Antineoplastic agents 2020-12 Incyte Corporation New active substance

Being reviewed under the Notice of Compliance with Conditions Guidance
Tazarotene Antipsoriatics 2020-09 Bausch Health, Canada Inc. Not applicable
Tecovirimat monohydrate Antivirals for systemic use 2021-02 SIGA Technologies, Inc. Extraordinary use submission

New active substance
Tozinameran** Vaccines 2021-06* Pfizer Canada ULC/BioNTech SE For use in relation to COVID-19

New active substance

Tralokinumab Other dermatological preparations 2020-12 Leo Pharma Inc New active substance

Part of 'aligned review' with a health technology assessment organization
Trastuzumab Antineoplastic agents 2018-02 Not available Not available
Trastuzumab Antineoplastic agents 2020-04 Samsung Bioepis Co., Ltd Biosimilar
Trastuzumab
(2 submissions under review)
Antineoplastic agents 2017-11 Not available Not available
Treosulfan Antineoplastic agents 2020-01 Marcan Pharmaceuticals Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance
Vericiguat Cardiac therapy 2021-01 Bayer Inc New active substance
Vitamin K1 Antihemorrhagics 2019-08 Marcan Pharmaceuticals Inc Being reviewed under the Submissions Relying on Third-Party Data Guidance
Whole virion inactivated coronavirus Vaccines 2021-06* Vaccigen Ltd Not applicable
Zanubrutinib Antineoplastic agents 2020-09 Beigene Switzerland GMBH Not applicable
Footnote *

This submission is being added to this list at the receipt of submission, and will be reviewed under expedited timelines, due to its relevance to the ongoing COVID-19 pandemic.

Return to footnote * referrer

This applicant has filed a new drug submission under the Food and Drug Regulations, to transition this product from the interim order. The product continues to be approved for sale in Canada during this transition period.

Return to footnote ** referrer

Report a problem or mistake on this page
Please select all that apply:

Thank you for your help!

You will not receive a reply. For enquiries, contact us.

Date modified: